摘要
近年来,化学治疗(化疗)在晚期非小细胞肺癌(NSCLC)治疗中的基石地位已经受到了严重的挑战,疗效已经遭遇瓶颈。通过化疗与分子靶向药物、抗血管生成药物或免疫治疗药物的联合应用,挖掘现有化疗药物的潜力并研发新型化疗药物,寻找预测化疗疗效的生物标志物等手段,有望最大程度让晚期NSCLC患者在化疗中获益。
Nowadays,the cornerstone status of chemotherapy in advanced non-small cell lung cancer(NSCLC)is seriously challenged and its therapeutic effect has hit the bottlenecks.With the combination of chemotherapy and molecular targeted drugs,antiangiogenic agents or immunotherapy drugs,tapping the potential of chemotherapeutic drugs and developing new chemotherapeutic drugs,searching the biomarkers that can predict the efficacy of chemotherapy,most patients with advanced NSCLC may get the maximum benefit from chemotherapy.
作者
章必成
朱波
ZHANG Bicheng;ZHU Bo(Department of Oncology,Renmin Hospital of Wuhan University,Wuhan 430060,China;Department of Oncology,Xinqiao Hospital,Army Medical University,Chongqing 400037,China)
出处
《医药导报》
CAS
北大核心
2018年第5期531-535,共5页
Herald of Medicine
